arrow_back Back to App

Biologic Drugs: New Rules for First Interchangeable Products

This act clarifies the exclusivity period for the first interchangeable biological products. This aims to provide certainty in the approval process, potentially impacting drug availability and costs for citizens.
Key points
The act defines when the first interchangeable biological product receives market exclusivity.
These changes could influence competition among biologic drug manufacturers, potentially affecting treatment access and costs for patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_4303
Sponsor: Sen. Kaine, Tim [D-VA]
Process start date: 2022-05-25